Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | CD229 as a potential therapeutic target for multiple myeloma

Carlos Fernández De Larrea • 10 Jun 2022
EHA 2022
Multiple Myeloma Smoldering Myeloma

Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, highlights the potential of CD229 as a therapeutic target in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Carlos Fernández De Larrea

Novel therapeutic strategies in multiple myeloma
Novel therapeutic strategies in multiple myeloma
Carlos Fernández De Larrea • 15 Apr 2023
Safety & efficacy cesnicabtagene autoleucel (ARI0002H) in R/R multiple myeloma
5:35
Safety & efficacy cesnicabtagene autoleucel (ARI0002H) in R/R multiple myeloma
Carlos Fernández De Larrea • 11 Jun 2022
Managing progression after BCMA-targeted therapy in R/R multiple myeloma
1:02
Managing progression after BCMA-targeted therapy in R/R multiple myeloma
Carlos Fernández De Larrea • 10 Jun 2022
Safety and efficacy of cesnicabtagene autoleucel (ARI0002h) for R/R MM
1:22
Safety and efficacy of cesnicabtagene autoleucel (ARI0002h) for R/R MM
Carlos Fernández De Larrea • 10 Jun 2022

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Carlos Fernández De Larrea • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Carlos Fernández De Larrea • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Carlos Fernández De Larrea • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Carlos Fernández De Larrea • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals